Ignite Creation Date:
2024-05-06 @ 9:52 AM
Last Modification Date:
2024-10-26 @ 12:20 PM
Study NCT ID:
NCT03093116
Status:
RECRUITING
Last Update Posted:
2024-02-07
First Post:
2017-03-06
Brief Title:
A Study of Repotrectinib TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements
Sponsor:
Organization:
Turning Point Therapeutics Inc
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
500
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: